JPMorgan analyst Eric Joseph raised the firm’s price target on PTC Therapeutics (PTCT) to $78 from $72 and keeps an Overweight rating on the ...

“L-tyrosine is a precursor to dopamine, the neurotransmitter that aids in motivation, mood regulation, and pleasure,” says Best. Studies have suggested limited benefit in individuals with low dopamine ...

Synlogic (NASDAQ:SYBX – Get Free Report) is expected to issue its quarterly earnings data on Tuesday, March 18th. Analysts ...

Given the chatter that this is a gold-standard ingredient for hair growth, you may be super tempted to hit "add to cart" on ...

A nutritionist has warned people to avoid constantly using sweeteners over sugar as she claims the former is 'worse' and can ...

A nutritionist has warned of the dangers of consuming too many sweeteners instead of sugar. Everyday household sugar, often ...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...

Synthetic biology specialist Synlogic will start phase 3 testing of a drug for rare metabolic disorder phenylketonuria (PKU) next year, after reporting solid proof-of-concept data.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

A rare disease in the US is one in 1,500, or fewer than 200,000 people, and an ultra-rare disease is one in 50,000 or fewer than than 6,000 people.